APA (7th ed.) Citation

Zhang, T., Chen, G., Liu, C., Zu, L., Wang, Q., Wang, Y., . . . Fang, Y. (2019). A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects. BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 33(1), 93-100. https://doi.org/10.1007/s40259-018-0326-x

Chicago Style (17th ed.) Citation

Zhang, Tan, et al. "A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals, and Gene Therapy 33, no. 1 (2019): 93-100. https://doi.org/10.1007/s40259-018-0326-x.

MLA (9th ed.) Citation

Zhang, Tan, et al. "A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals, and Gene Therapy, vol. 33, no. 1, 2019, pp. 93-100, https://doi.org/10.1007/s40259-018-0326-x.